Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-26 @ 3:18 PM
NCT ID:
NCT07457151
Eligibility Criteria:
Inclusion Criteria:
1. Patients eligible for and treated with Danicpan as add-on therapy to a C5 inhibitor (Eculizumab or Ravulizumab) in patient with PNH in Korea
2. Provision of a signed and dated written informed consent by the patient or their legally acceptable representative
Exclusion Criteria:
1. Participation in any concurrent interventional trials during the period of study drug treatment
2. Other off-label indications according to the approved label in Korea
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT07457151
Study Brief:
Protocol Section:
NCT07457151